News

In the studies 6-OHDA was primarily injected into the striatum on one side of each rat’s brain, enabling dopaminergic terminals to retract from the striatum towards the substantia

Under the collaboration, Lonza will develop and manufacture demcizumab, anti-Notch 2/3 projects, anti-Fzd7, anti-Notch, anti-DLL4/VEGF Bi-Specific, including many other monoclonal antibodies at its mammalian manufacturing facility in Slough,

As part of the contract, DSM will develop and manufacture Paranta’s lead recombinant human protein, follistatin. The agreement also represents DSM’s collaboration with an Australian customer at their

The report is based on the data collected from the observational study conducted by professor Michael Sobel, VA Puget Sound HCS and the University of Washington in patients

As part of the agreement, CSafe RKN will be added to Kuehne + Nagel’s health care product portfolio. Csafe president Brian Kohr said Csafe is happy to provide

DiFusion’s CleanFUZE has completed a series of in vivo and in vitro clinical tests, which showed that it could eradicate 99.998% of methicillin-resistant staphylococcus aureus bacteria and prevent

The randomised, double-blind Phase 2 study is designed to determine the safety and efficacy profile of TCN-032 in normal volunteers challenged with influenza A. All the subjects in

Under the strategic alliance, both the companies will offer contract development and manufacturing of ADCs by simplifying the supply chain and vendor management relationships. Fujifilm Diosynth Biotechnologies commercial

Hokusai-VTE Phase 3 study, which enrolled more than 8,250 patients from more than 400 clinical sites, will compare Edoxaban 60mg once-daily to warfarin control therapy. The double-dummy, event-driven,